^
Association details:
Evidence:
Evidence Level:
Sensitive: D – Preclinical
Source:
Title:

Kevetrin induces apoptosis in TP53 wild-type and mutant acute myeloid leukemia cells

Published date:
10/01/2020
Excerpt:
After continuous treatment, significant cell growth arrest and apoptosis were observed in all cell lines, with TP53‑mutant models displaying a higher sensitivity and p53 induction. Kevetrin also displayed efficacy against TP53 wild‑type and mutant primary AML, with a preferential cytotoxic activity against blast cells. Gene expression profiling revealed a common core transcriptional program altered by drug exposure and the downregulation of glycolysis, DNA repair and unfolded protein response signatures. These findings suggest that kevetrin may be a promising therapeutic option for patients with both wild‑type and TP53‑mutant AML.
DOI:
doi: 10.3892/or.2020.7730. Epub 2020 Aug 11.